A humbling setback for an immune-revving cancer therapy underscores the many questions facing the field – STAT
STAT |
A humbling setback for an immune-revving cancer therapy underscores the many questions facing the field
STAT “There has already been a lot of criticism of all the combination cancer immunotherapy studies going on, so I'm sure those critics will only grow louder,” said Brad Loncar, an independent investor who runs a fund focused on cancer immunotherapy. “But … Immunotherapy Shakeup: AstraZeneca Inks Merck Deal as Drug Combo Fails AstraZeneca shares plunge 16 percent as lung cancer study fails AstraZeneca's lung cancer immunotherapy trial fails to meet primary endpoint |
